linjc16/ctgov huggingface dataset:
The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID-19 Infection

Study Overview
=================
Brief Summary
-----------------
Pathogen-free, concentrated, pooled convalescent plasma has higher SARS-CoV2 antibody titers and neutralizing antibody activities, without requiring blood group compatibility that allows patient accessibility in a shorter time and has safe plasma characteristic.

Detailed Description
-----------------
The efficacy of SARS-CoV2 standard single donor convalescent plasma varied according to the application time and most importantly the amount of antibody that is administered. Single donor plasma has some drawbacks; such as the insufficient levels of neutralizing antibody activities, the requirements of blood group compatibility, and the risk of infection transmission. In this study, the efficacy and safety of pathogen inactivated, isohemagglutinin-depleted (concentrated) and pooled convalescent plasma was investigated.

Official Title
-----------------
The Effectiveness of ACB-IP 1.0 Universal Pathogen Free Concentrated Cocktail Convalescent Plasma in COVID-19 Infection

Conditions
-----------------
Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Are over the age of 60 or- Between the ages of 18-60, serious comorbidities (cancer, COPD, cardiovascular illness, hypertension, DM) Clinically diagnose COVID-19 or radiological diagnosed COVID-19 pnemonia Exclusion Criteria: Multiple Organ Failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Single donor convalescent plasma<br>Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with single donor plasma | |
| ACB- IP 1.0<br>Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with ACB- IP 1.0 pathogen-free concentrated cocktail convalescent plasma | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality Rate | A mortality rate is a measure of the frequency of occurrence of death in a defined population during a specified interval. | 6 Months | 
| Length of Hospitalization | The average length of stay in hospitals (ALOS) is often used as an indicator of efficiency | 6 Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Side Effects | Problems that occur when treatment goes beyond the desired effect. Or problems that occur in addition to the desired therapeutic effect. | 6 Months |
Optical Elastography of Systemic Sclerosis Skin

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to develop a new way to assess skin thickness in patients with scleroderma (systemic sclerosis). The study will test how well a new imaging method called optical coherence elastography (OCE) compares to the current clinical method used to estimate skin thickness, the modified Rodnan Skin Score (mRSS).

Official Title
-----------------
Optical Elastography of Systemic Sclerosis Skin

Conditions
-----------------
Scleroderma

Intervention / Treatment
-----------------
* Device: Optical Elastography
* Other: Visual Assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for scleroderma patients: meet the 2013 American College of Rheumatology and the European League Against Rheumatism (ACR/EULAR) criteria for systemic sclerosis with limited or diffuse cutaneous involvement Exclusion Criteria: have another skin disease other than systemic sclerosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Optical Elastography Assessment of Skin Thickness<br> | Device: Optical Elastography<br>* To image skin thickness, Optical Coherence Elastography (OCE)-scanning of 6 body surface areas will be preformed using the Phase-Stabilized Swept Source Optical Coherence Elastography (PhS-SSOCE) system.<br>|
| Visual Assessment of Skin Thickness<br> | Other: Visual Assessment<br>* Skin thickness will be visually assessed clinically in 6 body surface areas using the the modified Rodnan Skin Score (mRSS). The mRSS uses a 0-3 scale, where 0 = normal, 1= mild thickness, 2 = moderate thickness, and 3 = severe thickness<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Skin optical elastography (OCE) scan score |  | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Skin thickness as assessed by Modified Rodnan Skin Score (mRSS) |  | Baseline | 
| Fibrosis score as assessed by forearm skin punch biopsy | A score based on histological findings of skin punch biopsy will be calculated. There some minor risk involved with skin biopsy procedure. | Baseline | 
| Disability as assessed by the Scleroderma Health Assessment Questionnaire |  | Baseline |
Report 2 Cases of Massive Incarceration Necrosis Rectal Prolapse Are Successfully Treated With Altemeier's Procedure

Study Overview
=================
Brief Summary
-----------------
Incarceration and necrosis of rectal prolapse is rare and often requires urgent management. Perineal rectosigmoidectomy (Altemeir procedure) is a reasonable technique for this condition. The need for a diverting stoma depends on the patient's condition and the experience and judgement of the surgeon. A literature review was performed to determine optimal management of incarcerated and necrotic rectal prolapse, and to determine the indication for fecal diversion.

Official Title
-----------------
Report 2 Cases of Massive Incarceration Necrosis Rectal Prolapse Are Successfully Treated With Altemeier's Procedure

Conditions
-----------------
Rectal Prolapse

Intervention / Treatment
-----------------
* Procedure: perineal rectosigmoidectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 2 cases incarceration rectalprolapse Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 52 Years
Maximum Age: 69 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: incarceration rectal prolapse<br> | Procedure: perineal rectosigmoidectomy<br>* In an Altemeier perineal rectosigmoidectomy, a full-thickness circumferential incision is made in the prolapsed rectum about 1-2 cm from the dentate line (see the image below). The hernia sac is entered, and the prolapse is delivered. The mesentery of the prolapsed bowel is serially ligated until no further redundant bowel can be pulled down. The bowel is transected and either hand-sewn to the distal anal canal or stapled with a circular stapler. Before anastomosis, some surgeons plicate the levator ani muscles anteriorly, which may help improve continence.<br>* Other names: Altemeier's procedure;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| recurrent rectal prolapse | patients were asked for symptoms such as: pain during bowel movements, mucus or blood discharge from the protruding tissue, a loss of urge to defecate, awareness of something protruding upon wiping | 3 months after surgery |
Study of Neurological Damage From Coronavirus Disease (COVID-19)

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to support the exploration of the NEURO-COVID-19 database and in particular to carry out the post-treatments necessary to derive quantitative information on the characterization of the lesion load, in particular with regard to of the vascular tree

Official Title
-----------------
Study of Neurological Damage From Coronavirus Disease (COVID-19): Extraction of Quantitative Imaging Biomarkers for the Characterization of Pathological Profiles

Conditions
-----------------
COVID-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Adult patient (≥18 years old) COVID + patient presenting with neurological symptoms leading to an MRI. Patient taken care of in one of the care centers associated with this research Patient not having expressed his opposition, after information, to the reuse of his data for the purposes of this research. Exclusion criteria: Patient who expressed his opposition to participating in the study COVID patient not having neurological symptoms or not having received an MRI Patient under guardianship or guardianship Patient under legal protection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective study of the neurological damage in patients with Covid-19 |  | Files analysed retrospectively from January 01, 2020 to October 31, 2021 will be examined] | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, SARS-COV-2, Central nervous system, Headache, Loss of smell, Coma
Adjuvanted Influenza Vaccine Effectiveness in the Elderly (65+Yrs)

Study Overview
=================
Brief Summary
-----------------
This study explores the hypothesis that the use of an adjuvanted influenza vaccine in the elderly will produce greater vaccine effectiveness in their group.

Detailed Description
-----------------
To evaluate the effectiveness of adjuvanted trivalent inactivated influenza vaccine in the elderly (aged ≥ 65 years) through the reduction in relative risk of microbiologically confirmed influenza illness

Official Title
-----------------
A Case-Control Study to Evaluate the Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine in the Elderly Aged ≥65 Years.

Conditions
-----------------
Influenza

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1.Elderly tested for influenza as part of routine clinical care in the Lower Mainland and on Vancouver Island during the influenza season. Cases: Proven influenza diagnosed on naso-pharyngeal swab via PCR Controls: Elderly with influenza-like-illness testing negative for influenza during the influenza season. Exclusion Criteria: Known immunodeficiency disorders (including HIV) Current or recent (within 90 days prior to first dose of influenza vaccine) immunosuppressive treatment including chronic oral steroids (1mg/kg for > 4 weeks), cytotoxic chemotherapy, radiation therapy, other immunosuppressive drug and biologic agents Note: Use of topical or inhalant corticosteroids is acceptable. Administration of immunoglobulins during the study period;

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adjuvanted Vaccine Group<br> | |
| Unadjuvanted Vaccine Group<br> | |
| Unvaccinated Elderly<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vaccine effectiveness against laboratory confirmed influenza illness | Evaluation of the effectiveness of an adjuvanted TIV in the elderly aged ≥65 years, through the reduction in relative risk of microbiologically confirmed influenza illness | Influenza season 2011/12 and 2012/13 |
Selection of Embryos by Time-lapse

Study Overview
=================
Brief Summary
-----------------
In order to improve success rate by assisted reproductive techniques new techniques are being developed for selection of the embryo with best chance of implantation, establishement of pregnancy and subsequent delivery.The present study is based upon the hypothesis that time-lapse (frequent imaging) may give information about important steps in embryonic development, which could help to optimize selection of embryo(s) for treatment in IVF. The present study evaluates the outcome of conventional embryo culture with culture in a specially developed incubator equipped with a time-lapse system (Embryoscope). Embryos from 50 IVF cycles (400 embryos) will be randomised to either conventional incubation or to culture in the Embryoscope. Embryos will be cultured for five days to the blastocyst stage. The primary endpoint is fraction of embryos developed to the four cell stage.

Detailed Description
-----------------
In vitro fertilization for infertility has a success rate on average in Europe of 25% in terms of baby take-home rate per cycle. One way to improve this rather low succes rate is to develop new measures for selection of the best embryo among peers as presently evaluated by embryo morphology. One of these promising methods is contineous imaging of embryo development by time-lapse. A new and unique equipment for this purpose - an Embryoscope - har been developed by Unisense Fertilitech. The present study evaluates embryo 4-cell rate during cultivation to blastocyst stage in a conventional incubator with 4-cell rate in the Embryoscope to ensure non-inferiority of the latter.

Official Title
-----------------
Selection of Embryos for IVF Treatment by Time-lapse

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Device: Embryoscope


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing 2.nd or 3.rd IVF cycle with expected retrieval of 8 oocytes or more. Age < 38 years Exclusion Criteria: Endometriosis

Ages Eligible for Study
-----------------
Maximum Age: 37 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Embryoscope<br> | Device: Embryoscope<br>* The embryoscope is an incubator with in-built photographic equipment<br>|
| No Intervention: Conventional incubator<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 4-cell rate |  | 2 days after oocyte pick-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IVF, Infertility, embryo selection, embryoscope, time-lapse
Enhanced Recovery Programs and Small Bowel Obstruction

Study Overview
=================
Brief Summary
-----------------
Small bowel obstruction surgery is frequent and would benefit from enhanced recovery programs. While some studies advocate for their feasibility, it has never been proved and prospective studies are required to confirm the feasibility of such program and the impact on postoperative outcomes.

Official Title
-----------------
Feasability and Impact of Enhanced Recovery Programs After Surgery for Small Bowel Obstruction

Conditions
-----------------
Small Bowel Obstruction, Surgery

Intervention / Treatment
-----------------
* Procedure: Enhanced recovery program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adhesionnal small bowel obstruction requiring surgical management Exclusion Criteria: No surgery Patients disagreeing to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Enhanced recovery program<br> | Procedure: Enhanced recovery program<br>* 12 items of program (preoperative, peroperative postoperative) according to the enhanced recovery after surgery society<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| occurence rate of postoperative ileus |  | within 30 postoperative days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility of the enhanced recovery program after small bowel obstruction surgery | The feasibility of the enhanced recovery program will be assessed by using the ratio: number of items of the programs followed/ number of items in the programs | within 30 postoperative days | 
| Postoperative morbidity |  | within 30 postoperative days | 
| length of stay |  | the day of discharge assessed up to 30 days | 
| Rate of nasogastric tube replacement |  | within 30 postoperative days | 
| Rate of tolerance to solid food |  | within 30 postoperative days | 
| Time to GI function recovery |  | within 30 postoperative days | 
| acceptability toward the enhanced recovery program | The acceptability will be assessed through 2 qualitative questions and a 1-10 satisfaction scale | the day of discharge up to 30 days |
Emergency Department Telephone Quitline

Study Overview
=================
Brief Summary
-----------------
The purpose of this preliminary study was to evaluate the intervention completion rate among cigarette smokers enrolled through the Emergency Department (ED) in a tobacco quitline (QL) and to assess the feasibility of a randomized controlled trial assessing the efficacy of this intervention.

Detailed Description
-----------------
This pilot study was a prospective, randomized, controlled, un-blinded study using a convenience sample of cigarettes smokers recruited through the ED. Utilizing a computerized block randomization schedule, subjects were randomized in blocks of four to receive a proactive QL intervention through an established QL or a United States Public Health Service (USPHS) self-help manual. Proactive telephone counseling describes counseling that is initiated by a counselor rather than the subject. Both groups received strong advice to quit from study personnel. Names and telephone numbers of patients randomized to the QL group were faxed to the QL which then initiated contact with the patient. Multiple contact attempts were made over the following week by telephone. Patients in the QL were instructed to call the QL if they had not been reached in one week. QL counseling involved an initial 45-minute telephone session followed by up to four 10 to 15 minute follow-up sessions around their identified quit date. QL patients not successfully contacted within one week of enrollment were sent a letter inviting them to call as well as information on strategies to help them quit.

Official Title
-----------------
A Telephone Quitline Intervention for Smoking Cessation Through the Emergency Department

Conditions
-----------------
Tobacco Dependence

Intervention / Treatment
-----------------
* Behavioral: Telephone Quitline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: We enrolled patients aged 18 or older who reported current daily cigarette smoking for at least one year and who indicated an interest in attempting to quit smoking.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Telephone Quitline|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary outcome was completion of the QL intervention. |  |  |
Hypomagnesemia Associated With Proton-Pump Inhibitor Use

Study Overview
=================
Brief Summary
-----------------
Use of proton pump inhibitors has been associated with hypomagnesemia. However, various case-control or prospective studies have found conflicting results with regards to proton pump inhibitors use and development of hypomagnesemia. Our aim was to evaluate the likelihood that proton pump inhibitors contributed to severe hypomagnesemia in a retrospective cohort of patients admitted with severe hypomagenesemia. We also aimed to look for risk factors leading to development of hypomagnesemia amongst users of proton pump inhibitors

Official Title
-----------------
Hypomagnesemia Associated With Proton-Pump Inhibitor Use

Conditions
-----------------
Proton Pump Inhibitor Adverse Reaction, Hypomagnesemia, Arrhythmias, Cardiac, Seizures, Hypocalcemia, Hypokalemia

Intervention / Treatment
-----------------
* Drug: proton pump inhibitor use


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted with hypomagnesemia (cases) Patients prescribed with proton pump inhibitors (controls) Exclusion Criteria: Patients prescribed with less than three months duration of proton pump inhibitors (controls)

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Case<br>Patients admitted with hypomagnesemia are evaluated for proton pump inhibitor use and likelihood of hypomagnesemia due to proton pump inhibitor use | Drug: proton pump inhibitor use<br>* Patients using long term proton pump inhibitor<br>|
| Control<br>Patients on long-term proton pump inhibitor without documented hypomagnesemia | Drug: proton pump inhibitor use<br>* Patients using long term proton pump inhibitor<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hypomagnesemia due to use with proton pump inhibitor | Number of patients with Hypomagnesemia related to use of proton pump inhibitor using Naranjo score | 2013 to 2016 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factors for Hypomagnesemia | Odds ratio of developing Hypomagnesemia with risk factors of age, gender, type of drug, dose of drug, chronic renal failure, use of diuretics | 2013 to 2016 | 
| Hypocalcaemia | Number of patients developing hypocalcemia | 2013 to 2016 | 
| Hypokalemia | Number of patients developing Hypokalemia | 2013 to 2016 |